Clinical Trial Update: Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on the combination of Fluzoparib and Dalpiciclib for platinum-resistant recurrent ovarian cancer, with the study currently not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Fudan University | Conditions: Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING